GlobeNewswire Inc | Nov 13, 2020 09:15AM EST

November 13, 2020

BOSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020 at 1:45 pm ET.

To access the live webcast presentation, or the subsequent archived recording, please visit the Investors section of the Ziopharm website at www.ziopharm.com.

AboutZiopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharms pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viralSleeping Beautygene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufacturedSleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with theNational Cancer Institute,The University of Texas MD Anderson Cancer Centerand others. For more information, please visitwww.ziopharm.comInvestor Relations Contacts: Ziopharm Oncology: Chris Taylor VP, Investor Relations and Corporate Communications T: 617.502.1881 E:ctaylor@ziopharm.com

LifeSci Advisors: Mike Moyer Managing Director T: 617.308.4306 E:mmoyer@lifesciadvisors.comMedia Relations Contact: LifeSci Communications: Patrick Bursey T: 646.876.4932 E:pbursey@lifescicomms.com